Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (56.201)

71

Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis

enthalten in: Expert review of clinical pharmacology | 2024

von D'Haens, G. | Rosario, M. | Polhamus, D. | +7

72

Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia

enthalten in: Clinical rheumatology | 2024

von An, Q. | Ma, R. | Yuan, D. | +8

73

Sintilimab and Cardiovascular Toxicity

enthalten in: JAMA | 2024

von Peng, L. | Yang, D. | Weng, C.

CommentOn: JAMA. 2023 Dec 5;330(21):2064-2074. - PMID 38051328

74

Sintilimab and Cardiovascular Toxicity-Reply

enthalten in: JAMA | 2024

von Xu, J. | ORIENT-16 Investigators

CommentOn: JAMA. 2024 Apr 16;331(15):1333-1334. - PMID 38512227

75

In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control

enthalten in: Annals of internal medicine | 2024

von Stanbrook, M.

76

enthalten in: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | 2024

von Hansen, I. | Gebhardt, C. | Booken, N. | +1

77

Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease : a prospective study

enthalten in: International ophthalmology | 2024

von Lee, C. | Park, J. | Kim, Y. | +1

78

Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab

enthalten in: International ophthalmology | 2024

von Takizawa, H. | Yasuda, M. | Hoshi, K. | +3

79

Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma : the Notable-HCC phase 1b trial

enthalten in: Nature communications | 2024

von Li, Z. | Liu, J. | Zhang, B. | +14

80

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer

enthalten in: Journal for immunotherapy of cancer | 2024

von Meghani, K. | Frydenlund, N. | Yu, Y. | +2